stockrow
Friday 6 November 2026
Export MIRM’s income statement to Excel — free account
Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
93.82
0.28
+0.30%
Follow MIRM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.61 | 9.54 | 12.00 | 8.35 | |
P/FCF ratio |
132.73 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
653.56 | (23.77) | (167.66) | (1,299.29) | |
P/B ratio |
12.60 | 22.42 | 0.00 | 0.00 | |
Price to Tangible BV |
73.74 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.47 | 9.41 | 12.51 | 8.88 | |
EV/EBITDA |
1,011.60 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
69.71 | (31.35) | (34.02) | (21.97) | |
EV/FCF |
130.27 | (26.47) | (28.24) | (19.29) | |
Quick Ratio |
2.46 | 1.90 | 2.62 | 1.87 | |
Current Ratio |
2.67 | 2.09 | 2.86 | 2.07 | |
Net Debt/EBITDA |
(37.84) | 0.10 | (8.92) | (6.88) | |
Debt/Assets |
36.76% | 34.82% | 71.78% | 71.23% | |
Debt/Equity |
0.98 | 1.28 | (71.97) | (13.50) | |
Asset Turnover |
0.69 | 0.72 | 0.70 | 0.74 | |
Operating CF/Net income |
(1.06) | 0.29 | 0.66 | 0.11 | |
Capex/Depreciation |
(0.09) | (1.46) | (3.30) | (0.17) | |
Interest Coverage |
(1.27) | (218.33) | (16.25) | (37.20) | |
Research and Development Expense of Revenue |
34.32% | 515.51% | 60.69% | 65.38% | |
Selling, General and Administrative Expense of Revenue |
49.77% | 60.25% | 46.23% | 47.85% | |
Intangible Assets out of Total Assets |
0.31 | 0.29 | 0.24 | 0.27 | |
Share Based Compensation of Revenue |
12.77% | 22.64% | 17.35% | 17.94% | |
Graham Net Nets |
0.01 | (0.01) | (0.06) | (0.09) | |
Graham Number |
0.00 | 0.00 | 7.33 | 16.83 | |
Earnings Yield |
(0.60%) | (14.72%) | (12.42%) | (17.81%) | |
Free Cash Flow Yield |
0.75% | (3.73%) | (3.69%) | (5.51%) | |
Revenue per Share |
2.97 | 2.72 | 2.78 | 2.83 | |
Operating CF per Share |
0.12 | (3.89) | (0.70) | (0.07) | |
Capex per Share |
(0.01) | (0.18) | (0.39) | (0.02) | |
Free Cash Flow per Share |
0.11 | (4.07) | (1.09) | (0.09) | |
Cash per Share |
7.64 | 6.56 | 6.92 | 5.70 | |
Shareholders Equity per Share |
6.27 | 4.12 | (0.16) | (0.83) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.27 | 4.12 | (0.16) | (0.83) | |
Free Cash Flow |
5.47 | (239.43) | (69.27) | (5.62) | |
Working Capital |
343.89 | 296.61 | 413.52 | 303.55 | |
Capital Expenditures |
(0.60) | (10.66) | (25.02) | (1.30) | |
Net Current Asset Value |
21.56 | (78.99) | (419.09) | (494.17) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.07 | 0.14 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
100.81 | 114.48 | 126.10 | 131.74 | |
Average Payables |
12.12 | 35.52 | 20.54 | 12.91 | |
Average Inventory |
23.65 | 23.97 | 24.36 | 24.75 | |
Average Assets |
756.78 | 790.58 | 885.40 | 905.86 | |
Average Common Equity |
270.17 | 237.88 | 122.37 | 118.93 |
Columns are period end dates · fundamentals updated 5 Nov 2026